B Biesma
Overview
Explore the profile of B Biesma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Rouw N, Boosman R, van de Bruinhorst H, Biesma B, van den Heuvel M, Burger D, et al.
Lung Cancer
. 2020 Jun;
146:30-35.
PMID: 32505078
Introduction: Pemetrexed is a pharmacotherapeutic cornerstone in the treatment of non-small cell lung cancer. As it is primarily eliminated by renal excretion, adequate renal function is essential to prevent toxic...
2.
Dingemans A, Groen H, Herder G, Stigt J, Smit E, Bahce I, et al.
Ann Oncol
. 2015 Sep;
26(11):2286-93.
PMID: 26347109
Background: Nitroglycerin (NTG) increases tumor blood flow and oxygenation by inhibiting hypoxia-inducible-factor (HIF)-1. A randomized phase II study has shown improved outcome when NTG patches were added to vinorelbine/cisplatin in...
3.
Aerts J, Codrington H, Lankheet N, Burgers S, Biesma B, Dingemans A, et al.
Ann Oncol
. 2013 Aug;
24(11):2860-5.
PMID: 23986090
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer (NSCLC). However, in preclinical models and early phase noncomparative...
4.
van Riel S, Thunnissen E, Heideman D, Smit E, Biesma B
Ann Oncol
. 2012 Oct;
23(12):3188-3189.
PMID: 23079729
No abstract available.
5.
Biesma B, Wymenga A, Vincent A, Dalesio O, Smit H, Stigt J, et al.
Ann Oncol
. 2011 Jan;
22(7):1520-1527.
PMID: 21252061
Background: Elderly patients with advanced non-small-cell lung cancer (NSCLC) may derive similar benefit from platinum-based chemotherapy as younger patients. Quality of life (QoL) and comprehensive geriatric assessment (CGA) is often...
6.
van de Schans S, Janssen-Heijnen M, Biesma B, Smeenk F, van de Poll-Franse L, Seynaeve C, et al.
Eur J Cancer
. 2007 Sep;
43(15):2194-202.
PMID: 17884463
The purpose of this study was to document the influence of chronic obstructive pulmonary diseases (COPD) on stage at diagnosis, treatment strategy, and survival for unselected cancer patients (35 years...
7.
Janssen-Heijnen M, Lemmens V, van den Borne B, Biesma B, Oei S, Coebergh J
Crit Rev Oncol Hematol
. 2007 Jan;
62(2):172-8.
PMID: 17197191
Management of small cell lung cancer (SCLC) among elderly is complex because of decreased organ functions and interactions with comorbidity. Since elderly patients are often excluded from clinical trials, little...
8.
Efficace F, Bottomley A, Smit E, Lianes P, LeGrand C, Debruyne C, et al.
Ann Oncol
. 2006 Sep;
17(11):1698-704.
PMID: 16968876
Background: The aim of this prognostic factor analysis was to investigate if a patient's self-reported health-related quality of life (HRQOL) provided independent prognostic information for survival in non-small cell lung...
9.
Phernambucq E, Biesma B, Smit E, Paul M, vd Tol A, Schramel F, et al.
Br J Cancer
. 2006 Aug;
95(4):470-4.
PMID: 16909132
To assess the therapeutic activity of accelerated cisplatin and high-dose epirubicin with erythropoietin and G-CSF support as induction therapy for patients with stage IIIa-N2 non-small-cell lung cancer (NSCLC). Patients with...
10.
Biesma B, Manegold C, Smit H, Willems L, LeGrand C, Passioukov A, et al.
Eur J Cancer
. 2006 Jun;
42(10):1399-406.
PMID: 16759850
The objective of this phase II study was to document activity and toxicity of docetaxel and cisplatin as induction chemotherapy in patients with stage IIIA N2 non-small cell lung cancer...